Skip to content

Type: White Papers

Beyond Breakthrough: Optimizing the Breakthrough Therapy Designation

Multi-Cancer Early Detection Screening Tests: Considerations for Use of Real-World Data

Assessing the Use of ctDNA as an Early Endpoint in Early-Stage Disease

Optimizing Dosing in Oncology Drug Development

Expedited Development of Diagnostics for Therapies Targeting Rare Biomarkers or Indications

Harmonizing the Definition and Reported of Cytokine Release Syndrome (CRS) in Immuno-Oncology Clinical Trials

2018 Annual Meeting Panel 2: Exploring the Use of Circulating Tumor DNA as a Monitoring Tool for Drug Development

2018 Annual Meeting Panel 3: Real-Time Oncology Review and the Assessment Aid

2018 Annual Meeting Panel 1: Exploring Whether a Synthetic Control Arm Can Be Derived from Historical Clinical Trials that Match Baseline Characteristics and Overall Survival Outcome of a Randomized Control Arm

Optimizing the Use of Accelerated Approval